Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma Intracranial Hemangiopericytoma or Intracranial Hemangioblastoma

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    Memorial Sloan-Kettering Cancer Center
Updated on 7 November 2020

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying sunitinib to see how well it works in treating patients with recurrent or unresectable meningioma, intracranial hemangiopericytoma, or intracranial hemangioblastoma.

Description

OBJECTIVES: Primary - To evaluate the activity of sunitinib malate in patients with recurrent meningioma as measured by 6-month progression-free survival. Secondary - To describe the response rate, median time-to-progression, and overall survival in these patient. - To evaluate the safety of sunitinib malate in patients with recurrent meningioma. Exploratory - To develop exploratory data correlating response to the molecular phenotype of the tumor. - To develop exploratory data correlating serum angiogenic peptides, circulating endothelial cells (CEC) and circulating progenitor cells (CEP), and Dynamic Contrast Enhanced (DCE)-MRI with outcomes. OUTLINE: This is a multicenter study. Patients are stratified according to histology (benign vs malignant) and whether or not they have neurofibromatosis type 2 (yes vs no). Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 1 month and then periodically thereafter. PROJECTED ACCRUAL: A total of 50 patients (40 patients with meningioma and 10 patients with hemangiopericytomas/hemangioblastomas) will be accrued for this study.

Details
Condition Brain and Central Nervous System Tumors, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Precancerous Condition
Treatment sunitinib malate
Clinical Study IdentifierNCT00561665
SponsorMemorial Sloan-Kettering Cancer Center
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note